ENDRA Life Sciences (NDRA) Reports In-Line Q2 EPS

ENDRA Life Sciences (NASDAQ: NDRA) reported Q2 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on ENDRA Life Sciences (NDRA) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• KT&G approves KRW 360 billion share buyback and retirement plan
• BlockchainK2 plans private placement to raise up to $130,000